Bai Hao, Qiu Chengmiao, Fan Miaomiao, Zhong Yang, Yin Xiaolin, Zhang Tongchao, Chen Hao, Yang Xiaorong, Zhang Yuan, Lin Shujuan, Chen Liyong, Lv Ming
Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Qilu Hospital, Cheeloo College of Medicine, Clinical Research Center of Shandong University, Shandong University, Jinan, Shandong, China.
Nutr Metab (Lond). 2025 Jun 23;22(1):64. doi: 10.1186/s12986-025-00957-6.
The Life's Essential 8 (LE8) score, developed by the American Heart Association to evaluate cardiovascular health (CVH), was recently updated. Few studies have explored its effect on the incidence, progression, and prognosis of cardiometabolic multimorbidity (CMM). This study examines the association between the LE8 and the progress of CMM.
This prospective cohort study included 264,597 participants from the UK Biobank. CMM was defined as the presence of at least two of the three cardiometabolic diseases (CMDs): type 2 diabetes (T2D), stroke, and ischemic heart disease (IHD). Multi-state models were employed to investigate the relationship between the LE8 score and its subscales with risk of transitions from healthy to the onset of first cardiometabolic diseases (FCMD), followed by progression to CMM and to death.
Over a median follow-up of 13.94 years, 33,868 individuals developed at least one CMD, 4282 were diagnosed with CMM, and 4955 died. The results indicated that for each 1-SD increase in the LE8 score, a notable reduction was observed in the rate of progression from baseline to FCMD, baseline to death, and FCMD to CMM, with hazard ratios (HRs) of 0.64 (95% CI: 0.63, 0.65), 0.83 (95% CI: 0.81, 0.85), and 0.80 (95% CI: 0.78, 0.83), respectively. However, no correlation was found between the LE8 score and the transition from FCMD or CMM to death. By contrast, per 1-SD increment in the behavior scale score was associated with decreased risk of transition from FCMD to death (HR: 0.93; 95% CI: 0.90, 0.95) and from CMM to death (HR: 0.89; 95% CI: 0.88, 0.95), while per 1-SD increment in the biological scale score was associated with increased risk of transition from FCMD to death (HR: 1.10; 95% CI: 1.07, 1.14), and from CMM to death (HR: 1.22; 95% CI: 1.15, 1.29).
The LE8 defined CVH influences the progression from a healthy state to FCMD, CMM, and death, highlighting the importance of improving CVH as a comprehensive approach for preventing CMM.
美国心脏协会制定的用于评估心血管健康(CVH)的生命基本8要素(LE8)评分最近进行了更新。很少有研究探讨其对心脏代谢多重疾病(CMM)的发病率、进展和预后的影响。本研究考察LE8与CMM进展之间的关联。
这项前瞻性队列研究纳入了英国生物银行的264,597名参与者。CMM被定义为存在三种心脏代谢疾病(CMD)中的至少两种,即2型糖尿病(T2D)、中风和缺血性心脏病(IHD)。采用多状态模型来研究LE8评分及其子量表与从健康状态转变为首次发生心脏代谢疾病(FCMD)、随后进展为CMM以及死亡风险之间的关系。
在中位随访13.94年期间,33,868人发生了至少一种CMD,4282人被诊断为CMM,4955人死亡。结果表明,LE8评分每增加1个标准差,从基线到FCMD、基线到死亡以及从FCMD到CMM的进展率均显著降低,风险比(HR)分别为0.64(95%置信区间:0.63, 0.65)、0.83(95%置信区间:0.81, 0.85)和0.80(95%置信区间:0.78, 0.83)。然而,未发现LE8评分与从FCMD或CMM转变为死亡之间存在相关性。相比之下,行为量表评分每增加1个标准差,与从FCMD转变为死亡(HR:0.93;95%置信区间:0.90, 0.95)以及从CMM转变为死亡(HR:0.89;95%置信区间:0.88, 0.95)的风险降低相关,而生物量表评分每增加1个标准差,与从FCMD转变为死亡(HR:1.10;95%置信区间:1.07, 1.14)以及从CMM转变为死亡(HR:1.22;95%置信区间:1.15, 1.29)的风险增加相关。
LE8所定义的CVH会影响从健康状态到FCMD、CMM以及死亡的进展,凸显了改善CVH作为预防CMM的综合方法的重要性。